scholarly journals Electrophysiological study after ranibizumab in choroidal neovascularizat

2021 ◽  
pp. 3-13
Author(s):  
Mona Abdelkader ◽  
Ayman Fawzy ◽  
Wael El-doskey
Keyword(s):  
Visual Acuity ◽  
Intravitreal Injection ◽  
Choroidal Neovascularization ◽  
Electrophysiological Study ◽  
Multifocal Electroretinogram ◽  
Pattern Electroretinogram ◽  
Retinal Toxicity ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Subfoveal Choroidal Neovascularization

Purpose: To study the effects of intra-vitreal injection of ranibizumab on pattern electroretinogram (PERG) and multifocal electroretinogram(MF-ERG) parameters in choroidal neovascularization and to test the retinal toxicity of ranibizumab. Method: Fifty eyes of 50 patients with subfoveal choroidal neovascularization were included in the study. Thirty (30) eyes had neovascular age related macular degeneration (nAMD) and 20 eyes had myopic choroidal neovascularization. Ranibizumab was injected intravitreal monthly for3 months. Optical Coherence Tomography Angiography (OCT) was performed at the initial and final visits. Visual acuity, Pattern and multifocal electroretinography (PERG, MFERG) were performed before and at 1,2,3,6 months after intravitreal injection. Results: There was no clinical significant reduction of parameters of either MFERG or PERG after intravitreal injection of ranibizumab. There was significant increase in visual acuity, decrease in central macular thickness ,decrease in total macular volume and improvement in the parameters of both PERG and MFERG after intravitreal injection. Conclusion: Intravitreal injection of ranibizumab is effective in treatment CNV and safe. It has no retinal toxicity since no reduction in PERG& MFERG parameters. Keywords: AMD; Ranibizumab; PERG; MFERG

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin

2020 ◽  
pp. 231-238
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Macular Degeneration ◽  
Choroidal Neovascularization ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Photodynamic Treatment ◽  
Verteporfin Therapy ◽  
Age Related ◽  
Subfoveal Choroidal Neovascularization

In this chapter, report 1 of the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study details the one-year results of two double-masked, placebo-controlled, randomized clinical trials to determine whether photodynamic treatment with verteporfin reduces the risk of vision loss in patients with age-related macular degeneration (AMD) due to subfoveal choroidal neovascularization (CNV) measuring 5400 µm or less in greatest linear dimension with evidence of classic CNV and best-corrected visual acuity of approximately 20/40 to 20/200. At the month-12 examination, 61% of eyes assigned to verteporfin compared with 46% of eyes assigned to placebo had lost fewer than 15 letters of visual acuity from baseline). Verteporfin therapy was found to be safe and effective in reducing the risk of vision loss, and the authors recommended verteporfin therapy for treatment of patients with predominantly classic CNV from AMD.

scholarly journals Vision before and after scharioth macular lens implantation in patients with AMD: an electrophysiological study

2021 ◽  
Author(s):  
Jan Kremláček ◽  
Jana Nekolová ◽  
Markéta Středová ◽  
Jana Langrová ◽  
Jana Szanyi ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Peripheral Vision ◽  
Electrophysiological Study ◽  
Age Related Macular Degeneration ◽  
Peak Time ◽  
Pattern Reversal ◽  
Motion Onset ◽  
Age Related ◽  
Lens Implantation ◽  
Near Visual Acuity

Abstract Background For patients with age-related macular degeneration (AMD), a special intraocular lens implantation partially compensates for the loss in the central part of the visual field. For six months, we evaluated changes in neurophysiological parameters in patients implanted with a “Scharioth macula lens” (SML; a center near high add + 10 D and peripheral plano carrier bifocal lens designed to be located between the iris and an artificial lens). Methods Fourteen patients (5 M, 9 F, 63–87 years) with dry AMD were examined prior to and at 3 days after, as well as 1, 2, and 6 months after, implantation using pattern-reversal, motion-onset, and cognitive evoked potentials, psychophysical tests evaluating distant and near visual acuity, and contrast sensitivity. Results Near visual acuity without an external aid was significantly better six months after implantation than before implantation (Jaeger table median (lower; upper quartile): 4 (1; 6) vs. 15 (13; 17)). Distant visual acuity was significantly altered between the pre- (0.7 (0.5; 0.8) logMAR) and last postimplantation visits (0.8 (0.7; 0.8) logMAR), which matched prolongation of the P100 peak time (147 (135; 151) ms vs. 161 (141; 166) ms) of 15 arc min pattern-reversal VEPs and N2 peak time (191.5 (186.5; 214.5) ms vs. 205 (187; 218) ms) of peripheral motion-onset VEPs. Conclusion SML implantation significantly improved near vision. We also observed a slight but significant decrease in distant and peripheral vision. The most efficient electrophysiological approach to test patients with SML was the peripheral motion-onset stimulation, which evoked repeatable and readable VEPs.

Sign in / Sign up

Export Citation Format

Share Document